Health Care Down as Moderna Gives Back Some Gains - Health Care Roundup
Dow Jones
Aug 21
Health-care companies fell as euphoria about a breakthrough in RNA-based medicine faded.
Moderna shed almost one quarter of its value, giving back a chunk of the gains associated with Wednesday's disclosure of promising data on a cancer treatment. Moderna and Merck's jointly developed personalized cancer vaccine had stopped melanoma cancer from coming back or spreading in patients. The personalized nature of the vaccine and the relatively low occurrence of the melanoma strain of skin cancer could limit commercial potential.
For 2027, employers may be facing the biggest health-insurance increase in at least two decades.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.